21个基因检测评分在乳腺癌复发中的应用效果及影响因素研究

Values of 21 Genetic Markers Scoring for the Risk of Recurrence in Breast Cancer

目的探讨21基因检测复发评分在乳腺癌患者中的应用效果及影响因素.方法选择2014年6月~2017年8月科室收治的乳腺癌患者90例,入组患者雌激素受体(ER)阳性、人类表皮生长因子受体2(HER2)阴性.患者均行手术治疗,切除病灶组织,采用实时荧光聚合酶链反应(PCR)检测21基因(包括:16个乳腺癌相关基因及5个参考基因)表达,计算21基因复发风险评分.根据21基因复发风险评分将患者分为低危组(n=26例)、中危组(n=30例)和高危组(n=34例),分析21基因检测复发评分与乳腺癌病理的关系并进行多因素Logistic回归分析.结果单因素结果表明:21基因检测复发评分与乳腺癌患者年龄、病理类型、组织分级、P53、TOPIIa、EGFR、CK5/6及手术方式的关联差异无统计学意义(P>0.05);21基因检测复发评分与乳腺癌患者肿瘤直径、Ki67、PR阳性率的关联有统计学意义(P<0.05);多因素Logistic回归分析结果表明:21基因检测复发评分与乳腺癌患者肿瘤直径、ki67、PR阳性率的关联有统计学意义(P<0.05).结论将21基因检测复发评分用于乳腺癌患者中效果理想,其影响因素较多,加强21基因检测复发评分能评估预后,指导临床治疗.

Objective To investigate the therapeutic effect and correlation analysis of peripheral lymphocyte and neutrophil ratio(LNR)and ratio of lymphocytes to monocytes in patients with nasopharyngeal carcinoma before treatment.Methods We retrospectively analyzed the blood routine results of 160 cases of nasopharyngeal carcinoma treated by radiotherapy and chemotherapy of nasopharyngeal carcinoma in Cancer Hospital of Anhui Province from December 2015 to October 2017.The clinical stage included in this study was stageⅠin 6 cases,21 cases of stageⅡ,62 cases of stageⅢand 71 cases of stageⅣ.The levels of WBC,NEUT%and LY%of peripheral blood were detected by Sysmex-XE 5000 hematology analyzer,Monocyte percentage(MONO%)and other indicators,calculate the lymphocyte to neutrophil ratio(LNR),lymphocyte to monocyte ratio(LMR).Results There were no significant differences in WBC,NEUTR%,LYR%and LNR between NPC patients and controls(P>0.05).LNR and LMR of patients with stable nasopharyngeal carcinoma(P<0.05).Conclusions The determination of peripheral blood lymphocyte to neutrophil ratio,lymphocyte to monocyte ratio before treatment in patients with nasopharyngeal carcinoma can be used as evaluation index Pharyngeal cancer patients with progression-free survival and prognosis of useful indicators.